REGENXBIO to Hold May 8 Call on Q1 2024 Financial Results and Updates

ROCKVILLE, Md., May 1, 2024 -- REGENXBIO Inc. (Nasdaq: RGNX) has announced that it will hold a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ending March 31, 2024, along with recent operational highlights. The company has provided a registration link for the webcast, and analysts interested in the question and answer session can register through a different specified link. A replay of the webcast will be accessible on REGENXBIO's investor website approximately two hours post-conference. Participants are encouraged to join 15 minutes before the scheduled start time.

REGENXBIO Inc. is a prominent clinical-stage biotechnology firm dedicated to harnessing gene therapy's potential to enhance lives. Established in 2009, the company has been at the forefront of developing AAV Therapeutics, a pioneering class of gene therapy medications. REGENXBIO is working on advancing a pipeline of AAV Therapeutics targeting retinal and rare diseases. Notable projects include ABBV-RGX-314 for wet age-related macular degeneration (AMD) and diabetic retinopathy, developed in partnership with AbbVie, RGX-202 aimed at treating Duchenne muscular dystrophy, and RGX-121 for the treatment of MPS II.

The company’s therapeutic platform has already impacted thousands of patients, notably through Novartis' ZOLGENSMA, a treatment for children with spinal muscular atrophy. Designed as one-time treatments, AAV Therapeutics hold promise for transforming healthcare for millions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!